<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20240519061838N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-09-17</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>Examination of Ketogenic Diet on Seizure Control in Children with Refractory Status Epilepticus: A Clinical Trial</public_title>
      <acronym></acronym>
      <scientific_title>The Effect of Ketogenic Diet on Seizure Control in Children with Refractory Status Epilepticus: A Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-09-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>20</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/92649</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization will be performed using simple randomization on an individual basis. A random number table will be used for this purpose. Initially, each of the 20 eligible patients will be assigned numbers 1 to 20. Then, by referring to a random number table, starting from a specified point, random numbers will be sequentially extracted. Even numbers will be allocated to the intervention group and odd numbers to the control group. In case of encountering duplicate numbers or numbers outside the range, the next number will be used, and this process will continue until 10 patients are allocated to each group. The random sequence will be generated by an individual independent of the implementation team and placed in sequentially numbered, opaque, sealed envelopes (SNOSE). After confirming patient eligibility and obtaining informed consent, the relevant envelope will be opened by the attending nurse or physician (who has no role in outcome assessment) and the patient's group assignment will be revealed. Thus, the principal investigator, outcome assessor, and data collector will remain blinded to the patients' group allocations, Blinding description: Given the overt nature of the intervention (ketogenic diet compared to the standard hospital diet), blinding of patients, parents/legal guardians, and healthcare personnel (attending physicians, nurses, and dietitians) is not feasible, and these individuals will be aware of the patients' group assignments.

To minimize bias in the study, the outcome assessor (the pediatric neurologist responsible for interpreting EEG recordings and performing clinical seizure evaluations), data collectors, and the statistical analyst will be kept blinded to the patients' group allocations. This will be achieved as follows:

EEG recordings and clinical reports will be provided to the neurologist without any indication of the intervention or control group.

Data will be extracted from medical records and checklists by an individual who is not informed of the patient's group assignment.

The final data analysis will be performed by the statistician using codes A and B (without revealing the intervention or control group), and the code will be broken only after the completion of the statistical analyses.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Refractory Status Epilepticus.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The intervention group consists of 10 children with refractory status epilepticus hospitalized in the PICU who, in addition to standard treatment (antiseizure medications and anesthetics per hospital protocol), will receive a ketogenic diet with a 4:1 ratio (fat to protein + carbohydrates) via a nasogastric (NG) tube. The diet is initiated after an 8‑ to 12‑hour fasting period, with the initial dose set at one‑third of the daily caloric requirement, gradually reaching full calories over 3 days. In case of intolerance, the diet ratio will be reduced to 3:1 or 2:1. The intervention will continue for at least 7 days, with adverse effects monitored through blood glucose measurements every 6 hours, daily laboratory tests, and recording of gastrointestinal symptoms. The primary outcome is the cessation of clinical and EEG seizures within 7 days. Intervention 2: Control group: The control group consists of 10 children with refractory status epilepticus hospitalized in the PICU who will receive only standard treatment (antiseizure medications and anesthetics according to the hospital protocol) and will not receive the ketogenic diet. Their nutrition will be provided according to the standard hospital diet (via nasogastric tube or parenterally).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Due to the confidentiality of the information of the children participating in the intervention</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Khatereh Rezazadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mardani Azar Children Hospital, Mardani Azar Street, Khavaran Town</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5143377505</zip>
        <telephone>+98 41 3159 2106</telephone>
        <email>rezazadekhatere@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Khatereh Rezazadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mardani Azar Children Hospital, Mardani Azar Street, Khavaran Street</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5143377505</zip>
        <telephone>+98 41 3159 2106</telephone>
        <email>rezazadekhatere@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age between 1 month and 18 years.
Definite diagnosis of refractory status epilepticus based on the ILAE definition: failure to respond to two lines of therapy (first-line benzodiazepine and one second-line antiseizure medication, i.e., phenytoin, levetiracetam, or sodium valproate) for refractory status epilepticus; and failure to respond to the third-line therapy along with the induction of pharmacological coma for super-refractory status epilepticus.
Persistence of seizure activity (clinical or electroencephalographic) for at least 30 minutes despite receiving the aforementioned treatments.
Obtaining written informed consent from the parents or legal guardian of the patient.</inclusion_criteria>
      <agemin>1 month</agemin>
      <agemax>18 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Presence of absolute contraindications to the ketogenic diet: Fatty acid oxidation defects, Pyruvate kinase deficiency, Porphyria, Primary carnitine deficiency, GLUT1 deficiency
Severe liver failure (liver enzymes &gt; 3 times the upper limit of normal) or severe renal failure (GFR &lt; 30 ml/min)
Inherited congenital metabolic disorders (inborn errors of metabolism)
Unwillingness of the parents or legal guardian to continue participation in the study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G40</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Epilepsy and recurrent seizures</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The intervention group consists of 10 children with refractory status epilepticus hospitalized in the PICU who, in addition to standard treatment (antiseizure medications and anesthetics per hospital protocol), will receive a ketogenic diet with a 4:1 ratio (fat to protein + carbohydrates) via a nasogastric (NG) tube. The diet is initiated after an 8‑ to 12‑hour fasting period, with the initial dose set at one‑third of the daily caloric requirement, gradually reaching full calories over 3 days. In case of intolerance, the diet ratio will be reduced to 3:1 or 2:1. The intervention will continue for at least 7 days, with adverse effects monitored through blood glucose measurements every 6 hours, daily laboratory tests, and recording of gastrointestinal symptoms. The primary outcome is the cessation of clinical and EEG seizures within 7 days.</i_keyword>
      <i_keyword>Control group: The control group consists of 10 children with refractory status epilepticus hospitalized in the PICU who will receive only standard treatment (antiseizure medications and anesthetics according to the hospital protocol) and will not receive the ketogenic diet. Their nutrition will be provided according to the standard hospital diet (via nasogastric tube or parenterally).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Cessation of clinical and electroencephalographic seizures within 7 days of initiating the diet. Timepoint: Clinical seizures are monitored continuously throughout the 7-day study period, with the final EEG evaluation performed on day 7 to determine the primary outcome. Method of measurement: Clinically and using electroencephalography (EEG).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Time to ketosis. Timepoint: Daily from the start of the diet until day 7. Method of measurement: Urine ketone measurement using ketone strips or urinalysis.</sec_outcome>
      <sec_outcome>Metabolic acidosis. Timepoint: Daily during the 7-day study period. Method of measurement: Blood pH and bicarbonate measurement from arterial or venous blood samples.</sec_outcome>
      <sec_outcome>Hypoglycemia. Timepoint: Every 6 hours during the 7-day study period. Method of measurement: Blood glucose measurement using a glucometer.</sec_outcome>
      <sec_outcome>Hypertriglyceridemia. Timepoint: Daily during the 7-day study period. Method of measurement: Triglyceride measurement from blood samples (lipid profile).</sec_outcome>
      <sec_outcome>Gastrointestinal complications. Timepoint: Daily during the 7-day study period. Method of measurement: Recording in a gastrointestinal symptom checklist by nurses based on clinical observation.</sec_outcome>
      <sec_outcome>Urinary stones and hyperuricemia. Timepoint: Upon occurrence of symptoms or clinical need (as per the attending physician's judgment). Method of measurement: Kidney ultrasound (for stones) and serum uric acid testing.</sec_outcome>
      <sec_outcome>Length of stay in PICU. Timepoint: At the time of discharge from PICU (end of study period). Method of measurement: Extraction from patient medical records (recording admission and discharge dates).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-07-01</approval_date>
        <contact_name>Ethics committee of Tabriz University of Medical Science</contact_name>
        <contact_address>Pediatric Health Research Center, Mardani Azar Children Hospital, Mardani Azar Street, Khavaran Town Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
